Omega-3 Fatty Acids for Cardioprotection

Slides:

Advertisements

Similar presentations

Weng TC, et al. J Clin Pharm Ther 2010;35:

Advertisements

Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Omega-3 Polyunsaturated Fatty Acids and Cardiovascular.

Date of download: 7/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Fish Intake, Contaminants, and Human Health: Evaluating.

Dyslipidemia and Diabetic Macular Edema

Michael J. Koren, MD, Michael H. Davidson, MD, Daniel J

A clinically practicable diagnostic score for metabolic syndrome improves its predictivity of diabetes mellitus: The Gruppo Italiano per lo Studio della.

Volume 36, Issue 9, Pages (September 2016)

Copyright © 2011 American Medical Association. All rights reserved.

From Inuit to Implementation: Omega-3 Fatty Acids Come of Age

Use of supplemental long-chain omega-3 fatty acids and risk for cardiac death: An updated meta-analysis and review of research gaps Kevin C. Maki, PhD,

A Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies of Eicosapentaenoic and Docosahexaenoic Long-Chain Omega-3 Fatty Acids.

Copyright © 2012 American Medical Association. All rights reserved.

Personalized Activity Intelligence (PAI) for Prevention of Cardiovascular Disease and Promotion of Physical Activity Bjarne M. Nes, PhD, Christian R.

A Blend of Sesame and Rice Bran Oils Lowers Hyperglycemia and Improves the Lipids Sankar Devarajan, PhD, Biprabuddha Chatterjee, MSc, Hidenori Urata,

Longitudinal Patterns of Cardiorespiratory Fitness Predict the Development of Hypertension Among Men and Women Xuemei Sui, MD, MPH, PhD, Mark A. Sarzynski,

“Sick Fat,” Metabolic Disease, and Atherosclerosis

Long-term Medical Management of the Liver Transplant Recipient: What the Primary Care Physician Needs to Know Siddharth Singh, MD, Kymberly D. Watt,

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis? Sripal Bangalore, MD,

“Sick Fat,” Metabolic Disease, and Atherosclerosis

A Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies of Eicosapentaenoic and Docosahexaenoic Long-Chain Omega-3 Fatty Acids.

James H. O’Keefe, MD, Salman K. Bhatti, MD, Ata Bajwa, MD, James J

Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart.

A Blend of Sesame and Rice Bran Oils Lowers Hyperglycemia and Improves the Lipids Sankar Devarajan, PhD, Biprabuddha Chatterjee, MSc, Hidenori Urata,

Dose-Response Relationship Between Severe Hypercholesterolemia and Body Mass Index in Healthy Young Adults Tomohide Yamada, MD, PhD, Shintaro Yanagimoto,

William L. Lanier, MD Mayo Clinic Proceedings

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,

An assessment by the Statin Diabetes Safety Task Force: 2014 update

Martin W. Schoen, MD, MPH, Joanne Salas, MPH, Jeffrey F

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

Junxiu Liu, MD, Xuemei Sui, MD, PhD, Carl J. Lavie, MD, James R

The Chemical Differences Between EPA and DHA.

Jari A. Laukkanen, MD, PhD, Tanjaniina Laukkanen, MSc, Setor K

Combined Association of Cardiorespiratory Fitness and Body Fatness With Cardiometabolic Risk Factors in Older Norwegian Adults: The Generation 100 Study

Dose-Response Relationship Between Severe Hypercholesterolemia and Body Mass Index in Healthy Young Adults Tomohide Yamada, MD, PhD, Shintaro Yanagimoto,

Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial Erik S.G. Stroes, MD, PhD, Andrey.

Cardiovascular Disease Resulting From a Diet and Lifestyle at Odds With Our Paleolithic Genome: How to Become a 21st-Century Hunter-Gatherer James H.

Omega-3 Fatty Acid Therapy: The Tide Turns for a Fish Story

Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:

A System-Based Approach to Depression Management in Primary Care Using the Patient Health Questionnaire-9 Ramona S. DeJesus, MD, Kristin S. Vickers,

Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)

A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia Gisle Langslet, MD, Andrei Breazna, PhD, Euridiki.

Body Composition and Heart Failure Prevalence and Prognosis: Getting to the Fat of the Matter in the “Obesity Paradox” Carl J. Lavie, MD, Richard V.

Coronary Artery Disease: A Continuum, Not a Threshold

James H. O'Keefe, M.D., Carl J. Lavie, M.D., Ben D. McCallister, M.D.

Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M

Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E

Comparative effects of an acute dose of fish oil on omega-3 fatty acid levels in red blood cells versus plasma: Implications for clinical utility William.

Personalized Activity Intelligence (PAI) for Prevention of Cardiovascular Disease and Promotion of Physical Activity Bjarne M. Nes, PhD, Christian R.

To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B? Carl J. Lavie, MD, Richard V. Milani, MD, James.

Lipid Profiles in Out-of-Hospital Sudden Unexpected Death

Effects of Statins on Renal Function

Daan Kromhout, et al. NEJM epub August 29, 2010

Cardiovascular Disease in Type 2 Diabetes: A Review of Sex-Related Differences in Predisposition and Prevention Abdallah Al-Salameh, MD, Philippe Chanson,

Association Between Caffeine Intake and All-Cause and Cause-Specific Mortality: A Population-Based Prospective Cohort Study Tetsuro Tsujimoto, MD, PhD,

Running and Mortality: Is More Actually Worse?

Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials Allan D. Sniderman, MD, James A. Sloand,

Elevated High-Density Lipoprotein Cholesterol Is Associated with Hyponatremia in Hypertensive Patients Ariel Israel, MD, PhD, Ehud Grossman, MD The.

From Inuit to Implementation: Omega-3 Fatty Acids Come of Age

Rhanderson Cardoso, MD, Roger S

Strategies for Optimizing Glycemic Control and Cardiovascular Prognosis in Patients With Type 2 Diabetes Mellitus James H. O'Keefe, MD, Mohammad Abuannadi,

Effects of Niacin on Glucose Control in Patients With Dyslipidemia

Medical Treatment of Overactive Bladder: In Response

Fish oil for prevention of sudden death in hemodialysis patients?

Ross Arena, PhD, PT, FAHA, Carl J. Lavie, MD Mayo Clinic Proceedings

Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease Dean G. Karalis, MD Mayo Clinic Proceedings

Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm

Is There an “Asymptote of Gain” Beyond Which Further Increases in Cardiorespiratory Fitness Convey No Additional Benefits on Mortality and Atrial Fibrillation?

Autonomic Tone and Benefits of Cardiac Rehabilitation Programs

Association of Elevated Triglycerides With Increased Cardiovascular Risk and Direct Costs in Statin-Treated Patients Peter P. Toth, MD, PhD, Sephy Philip,

Presentation transcript:

Omega-3 Fatty Acids for Cardioprotection John H. Lee, MD, James H. O'Keefe, MD, Carl J. Lavie, MD, Roberto Marchioli, MD, William S. Harris, PhD Mayo Clinic Proceedings Volume 83, Issue 3, Pages 324-332 (March 2008) DOI: 10.4065/83.3.324 Copyright © 2008 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 1 Time course of clinical events in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione study. Treatment with 850 mg/d of omega-3 acid ethyl esters reduced total mortality (left) by 21% and sudden cardiac death (right) by 45% at 3.5 years. CI = confidence interval; HR = hazard ratio. Data from reference 7. Mayo Clinic Proceedings 2008 83, 324-332DOI: (10.4065/83.3.324) Copyright © 2008 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 2 Eicosapentaenoic acid (EPA) (1.8 g/d) reduced the incidence of major adverse coronary events in the Japan EPA Lipid Intervention Study (JELIS) by 19%. CI = confidence interval. From The Lancet,8 with permission from Elsevier. Mayo Clinic Proceedings 2008 83, 324-332DOI: (10.4065/83.3.324) Copyright © 2008 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 3 Effect of prescription omega-3 acid ethyl esters (P-OM3) (4.0 g/d) on lipid and lipoprotein levels in statin-treated patients with serum triglyceride (TG) levels of 200-499 mg/dL (2.26-5.64 mmol/L). Median percent changes are presented for non-high-density lipoprotein cholesterol (non-HDL-C), TGs, calculated very-low-density lipoprotein cholesterol (VLDL-C), and low-density lipoprotein cholesterol (LDL-C) from baseline to the end of treatment.a P<.05. From Clin Ther,24 with permission from Excerpta Medica, Inc. Mayo Clinic Proceedings 2008 83, 324-332DOI: (10.4065/83.3.324) Copyright © 2008 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 4 Schema of potential dose responses and time courses for altering clinical events of physiologic effects of fish or fish oil intake. BP = blood pressure; DHA = docosahexaenoic acid; EPA = eicosapentaenoic acid. From JAMA,31 Copyright © 2006, American Medical Association. All rights reserved. Mayo Clinic Proceedings 2008 83, 324-332DOI: (10.4065/83.3.324) Copyright © 2008 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 5 Outcomes in children according to tertiles of weekly seafood consumption by the mothers during pregnancy: the Avon Longitudinal Study of Parents and Children (ALSPAC). IQ = intelligence quotient. From The Lancet,43 with permission from Elsevier. Mayo Clinic Proceedings 2008 83, 324-332DOI: (10.4065/83.3.324) Copyright © 2008 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 6 Relative risk of sudden cardiac death according to baseline blood levels of omega-3 fatty acids as percentage of total fatty acids. Data from reference 47. Mayo Clinic Proceedings 2008 83, 324-332DOI: (10.4065/83.3.324) Copyright © 2008 Mayo Foundation for Medical Education and Research Terms and Conditions